Viridian Therapeutics Inc (VRDN)

$14.66 -0.05 (-0.34%)
Market Cap 1.20B
Revenue (ttm) 300,000.00
Net Income (ttm) -269.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,983.33%
Debt to Equity Ratio 0.03
Volume 554,400
Avg Vol 823,234
Day's Range N/A - N/A
Shares Out 81.59M
Stochastic %K 18%
Beta 0.41
Analysts Strong Sell
Price Target $38.33

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 401, Waltham, United States
FelixH86
FelixH86 Jun. 22 at 8:08 AM
$VRDN dip to 13 dollar?..
0 · Reply
CDMO
CDMO Jun. 17 at 5:44 PM
$VRDN brutal
1 · Reply
Butch44
Butch44 Jun. 17 at 5:17 PM
$VRDN looks like another attack on your shares. Don't give them up cheaply.
1 · Reply
Tdorsey1776
Tdorsey1776 Jun. 11 at 2:18 PM
$VRDN $30-40 sometime in 2026. Its just a matter of patience. GLTA
0 · Reply
Butch44
Butch44 Jun. 11 at 2:09 PM
$VRDN nobody selling. Curious if we get one more short attack before meaningful data comes out.
1 · Reply
buylowandwait
buylowandwait Jun. 10 at 4:55 PM
$VRDN will a better mousetrap in a smallish company translate into financial success competing with a giant? Is there any company interested in acquiring this company? I have small speculative position acquired right after MFN mess, it is looking good so far...
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 10 at 12:31 PM
$VRDN Better than Tepezza.
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 10 at 12:05 PM
$VRDN SA piece posted: "Approximately 190,000 Americans have active or chronic TED. Currently, these conditions are treated by teprotumamab which was approved in 2020. Teprotumamab is better known as Tepezza and did $460 million of sales for Amgen (AMGN) in Q4 2024. It currently costs around $500,000 for a full regimen. Tepezza has treated approximately 15,000 patients. Viridian is building potentially 'best of breed' products in this niche, with better infusion times and shorter courses of therapy."
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 9 at 3:25 PM
$VRDN This is one of those back burner bios that will start cooking again soon. Patience......
0 · Reply
Butch44
Butch44 Jun. 6 at 3:46 PM
$VRDN buying every dip
0 · Reply
Latest News on VRDN
Viridian Therapeutics: The Song Remains The Same

Jun 9, 2025, 6:18 PM EDT - 15 days ago

Viridian Therapeutics: The Song Remains The Same

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 7:00 AM EDT - 20 days ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 30, 2025, 7:00 AM EDT - 26 days ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 20, 2025, 7:00 AM EDT - 5 weeks ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 7, 2025, 4:15 PM EDT - 6 weeks ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 7 weeks ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Apr 7, 2025, 7:00 AM EDT - 2 months ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Mar 2, 2025, 7:36 AM EST - 4 months ago

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 4 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Jan 8, 2025, 7:00 AM EST - 6 months ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Dec 19, 2024, 10:34 AM EST - 6 months ago

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Dec 18, 2024, 10:56 AM EST - 6 months ago

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Dec 17, 2024, 12:41 PM EST - 6 months ago

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Dec 16, 2024, 7:10 AM EST - 6 months ago

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Dec 16, 2024, 7:00 AM EST - 6 months ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Dec 13, 2024, 6:00 PM EST - 6 months ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Nov 12, 2024, 7:00 AM EST - 8 months ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics' Superior Prospects Make It A Buy

Oct 23, 2024, 4:02 PM EDT - 8 months ago

Viridian Therapeutics' Superior Prospects Make It A Buy

3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 9 months ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

AUPH CORT

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Sep 11, 2024, 11:25 PM EDT - 10 months ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Sep 10, 2024, 5:09 PM EDT - 10 months ago

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Sep 10, 2024, 4:01 PM EDT - 10 months ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Sep 10, 2024, 7:18 AM EDT - 10 months ago

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Sep 10, 2024, 7:00 AM EDT - 10 months ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Sep 9, 2024, 4:01 PM EDT - 10 months ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:15 AM EDT - 11 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 11 months ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRNA

3 Biotech Names With Potential Catalysts By Year End

Jul 29, 2024, 3:32 PM EDT - 11 months ago

3 Biotech Names With Potential Catalysts By Year End

CADL RCKT

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Jul 25, 2024, 8:00 AM EDT - 11 months ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 12, 2024, 10:29 AM EDT - 1 year ago

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Jun 11, 2024, 6:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 31, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 10, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:27 PM EDT - 1 year ago

Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

May 7, 2024, 7:33 PM EDT - 1 year ago

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 8:00 AM EST - 1 year ago

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:01 PM EST - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Feb 16, 2024, 8:00 AM EST - 1 year ago

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2024, 4:01 PM EST - 1 year ago

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Jan 17, 2024, 10:00 PM EST - 1 year ago

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Jan 8, 2024, 8:00 AM EST - 1 year ago

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023

Dec 29, 2023, 11:23 AM EST - 1 year ago

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023

Wedbush's Laura Chico talks biotech investing in 2024

Dec 26, 2023, 5:21 PM EST - 1 year ago

Wedbush's Laura Chico talks biotech investing in 2024

EWTX IBB NBIX XBI

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Dec 18, 2023, 7:00 AM EST - 1 year ago

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Best Small-Cap Stocks to Buy for 2024 and Beyond

Dec 14, 2023, 1:24 PM EST - 1 year ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH IMVT PRVA

Viridian: Market May Be Wrong In Its Disapproval

Dec 12, 2023, 8:00 AM EST - 1 year ago

Viridian: Market May Be Wrong In Its Disapproval

FelixH86
FelixH86 Jun. 22 at 8:08 AM
$VRDN dip to 13 dollar?..
0 · Reply
CDMO
CDMO Jun. 17 at 5:44 PM
$VRDN brutal
1 · Reply
Butch44
Butch44 Jun. 17 at 5:17 PM
$VRDN looks like another attack on your shares. Don't give them up cheaply.
1 · Reply
Tdorsey1776
Tdorsey1776 Jun. 11 at 2:18 PM
$VRDN $30-40 sometime in 2026. Its just a matter of patience. GLTA
0 · Reply
Butch44
Butch44 Jun. 11 at 2:09 PM
$VRDN nobody selling. Curious if we get one more short attack before meaningful data comes out.
1 · Reply
buylowandwait
buylowandwait Jun. 10 at 4:55 PM
$VRDN will a better mousetrap in a smallish company translate into financial success competing with a giant? Is there any company interested in acquiring this company? I have small speculative position acquired right after MFN mess, it is looking good so far...
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 10 at 12:31 PM
$VRDN Better than Tepezza.
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 10 at 12:05 PM
$VRDN SA piece posted: "Approximately 190,000 Americans have active or chronic TED. Currently, these conditions are treated by teprotumamab which was approved in 2020. Teprotumamab is better known as Tepezza and did $460 million of sales for Amgen (AMGN) in Q4 2024. It currently costs around $500,000 for a full regimen. Tepezza has treated approximately 15,000 patients. Viridian is building potentially 'best of breed' products in this niche, with better infusion times and shorter courses of therapy."
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 9 at 3:25 PM
$VRDN This is one of those back burner bios that will start cooking again soon. Patience......
0 · Reply
Butch44
Butch44 Jun. 6 at 3:46 PM
$VRDN buying every dip
0 · Reply
BioRich
BioRich Jun. 4 at 10:37 PM
$VRDN Very new to this one. Curious what the Bear case is for it. Thanks in advance for the help!
0 · Reply
buylowandwait
buylowandwait Jun. 2 at 4:18 PM
$APLS Commercial stage bios are having a solid day today with BPMC acquisition news. I see further development in bio M&A later this year given the depressed valuation and patent cliff. APLS should benefit as many others, $SNDX, $TGTX, $ARDX, $VRDN
2 · Reply
WoldanStanford
WoldanStanford Jun. 2 at 2:27 PM
$MLGO ->> $CABA $NTLA $VRDN https://m.youtube.com/shorts/tJBI9cE_CcI
0 · Reply
WoldanStanford
WoldanStanford May. 30 at 7:46 AM
$MLGO mlgo losers go for $CABA or $VRDN
2 · Reply
WoldanStanford
WoldanStanford May. 29 at 2:22 PM
$MLGO $CABA $VRDN @DaBullRunner https://m.youtube.com/shorts/6MX7Q59rUBM
0 · Reply
Winning_calls
Winning_calls May. 27 at 6:19 PM
$VRDN 🤞🤞
0 · Reply
Winning_calls
Winning_calls May. 27 at 1:24 AM
$VRDN pick me up @ $13.70
0 · Reply
type12
type12 May. 24 at 3:53 PM
$VRDN https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-Positive-Long-Term-Durability-Data-from-the-Veligrotug-Phase-3-THRIVE-Clinical-Trial-in-Patients-with-Active-Thyroid-Eye-Disease-TED/default.aspx
0 · Reply
WoldanStanford
WoldanStanford May. 23 at 8:25 PM
$CABA $MLGO $VRDN moved from mlgo to CABA tp 3.50$, then going to vrdn thats my plan to get 200% until eoy (not a f advoce) gl everyone
0 · Reply
type12
type12 May. 21 at 6:17 PM
$VRDN The company noted that it intends to submit a Biologics License Application for veligrotug for the treatment of TED in the second half of 2025, with a potential launch in 2026 pending approval. Watch this one buy the dips… They are working on various subcutaneous administrations and results for chronic TED look excellent. As there is no current competition for Tepezza and VRDN is well into their clinicals and the side effects profile is so much better compared to tepezza, Little doubt it will be approved. Easily $40-$60 Q1/2 2026. Just a thought. ✌🏼
0 · Reply
type12
type12 May. 21 at 5:46 AM
$VRDN 1st Approval sometime Q1 2026
1 · Reply
CDMO
CDMO May. 20 at 6:12 PM
$VRDN rocket is launching
0 · Reply